董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Geno Germano | 男 | Director | 65 | 未披露 | 未持股 | 2026-03-12 |
| Michael Amoroso | -- | Chief Executive Officer and Director and President | 48 | 未披露 | 未持股 | 2026-03-12 |
| Shari Lisa Piré | -- | Director | 61 | 未披露 | 未持股 | 2026-03-12 |
| Melinda Brown | -- | Director | 69 | 未披露 | 未持股 | 2026-03-12 |
| Stanley Frankel | -- | Director | 67 | 未披露 | 未持股 | 2026-03-12 |
| Kevin Buehler | 男 | Chair of the Board and Director | 68 | 36.20万美元 | 未持股 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dario Scimeca | 男 | General Counsel and Secretary | 51 | 171.02万美元 | 未持股 | 2026-03-12 |
| Michael Amoroso | -- | Chief Executive Officer and Director and President | 48 | 未披露 | 未持股 | 2026-03-12 |
| John Alexander Kelly | -- | Chief Financial Officer | 59 | 未披露 | 未持股 | 2026-03-12 |
| Jeff Smith | -- | Chief Research Officer | 52 | 未披露 | 未持股 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- Geno Germano
-
Geno Germano自2018年8月起担任生物技术公司Lucida Oncology，Inc.的总裁兼首席执行官兼董事会成员。作为Lucida的总裁兼首席执行官，Germano先生领导战略努力，在诊断成像，手术和治疗应用程序中利用Lucida’；s的超小型C点癌症靶向粒子平台。他于2016年6月至2017年3月担任生物学工程和产业化领导者Intrexon Corporation（Intrexon”；）总裁。在加入Intrexon之前，Germano从2014年到2016年2月担任辉瑞公司（Pfizer）全球创新制药业务集团总裁，在那里，他领导着一个不断增长的全球140亿美元的业务，涉及市场领先的药物和几个治疗领域的广泛的后期开发候选产品组合，包括心血管、代谢疾病、神经科学、炎症、免疫学和罕见疾病。Germano先生还是辉瑞（Pfizer）投资组合战略和投资委员会的联合主席，专注于从2013年至2016年在辉瑞（Pfizer）投资组合中实现研究与开发投资回报最大化。此前，从2009年到2013年，Germano先生担任辉瑞公司（Pfizer&8217；）专业护理和肿瘤业务部门的总裁兼总经理，他在该部门领导全球市场的商业、医疗和概念验证后的管道战略和开发，并担任疫苗业务的执行Vice President。Germano先生目前还在SageTherapeutics，Inc.董事会任职。从2008年到2018年，Germano先生是奥尔巴尼药学与健康科学学院的受托人。Germano先生在奥尔巴尼药学院（Albany College of Pharmacy）获得药学理学学士学位。
Geno Germano has served as President and Chief Executive Officer and as a board member of Elucida Oncology, Inc. "Elucida", a biotechnology company, since August 2018. As President and CEO of Elucida, Mr. Germano leads strategic efforts to utilize Elucida's ultra-small C-dot cancer targeting particle platform across diagnostic imaging, surgical and therapeutic applications. He served as President of Intrexon Corporation ("Intrexon"), a leader in engineering and industrialization of biology, from June 2016 to March 2017. Prior to joining Intrexon, from 2014 to February 2016 Mr. Germano was Group President of the Global Innovative Pharma Business of Pfizer Inc. ("Pfizer"), where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer, focused on maximizing the return on research and development investment across the Pfizer portfolio from 2013 to 2016. Previously, from 2009 through 2013 Mr. Germano served as President and General Manager of Pfizer's Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets, and as Executive Vice President of the Vaccines Business. Mr. Germano also currently serves on the board of Sage Therapeutics, Inc. From 2008 to 2018 Mr. Germano was a Trustee of the Albany College of Pharmacy & Health Sciences. Mr. Germano received his Bachelor of Science in Pharmacy from Albany College of Pharmacy. - Geno Germano自2018年8月起担任生物技术公司Lucida Oncology，Inc.的总裁兼首席执行官兼董事会成员。作为Lucida的总裁兼首席执行官，Germano先生领导战略努力，在诊断成像，手术和治疗应用程序中利用Lucida’；s的超小型C点癌症靶向粒子平台。他于2016年6月至2017年3月担任生物学工程和产业化领导者Intrexon Corporation（Intrexon”；）总裁。在加入Intrexon之前，Germano从2014年到2016年2月担任辉瑞公司（Pfizer）全球创新制药业务集团总裁，在那里，他领导着一个不断增长的全球140亿美元的业务，涉及市场领先的药物和几个治疗领域的广泛的后期开发候选产品组合，包括心血管、代谢疾病、神经科学、炎症、免疫学和罕见疾病。Germano先生还是辉瑞（Pfizer）投资组合战略和投资委员会的联合主席，专注于从2013年至2016年在辉瑞（Pfizer）投资组合中实现研究与开发投资回报最大化。此前，从2009年到2013年，Germano先生担任辉瑞公司（Pfizer&8217；）专业护理和肿瘤业务部门的总裁兼总经理，他在该部门领导全球市场的商业、医疗和概念验证后的管道战略和开发，并担任疫苗业务的执行Vice President。Germano先生目前还在SageTherapeutics，Inc.董事会任职。从2008年到2018年，Germano先生是奥尔巴尼药学与健康科学学院的受托人。Germano先生在奥尔巴尼药学院（Albany College of Pharmacy）获得药学理学学士学位。
- Geno Germano has served as President and Chief Executive Officer and as a board member of Elucida Oncology, Inc. "Elucida", a biotechnology company, since August 2018. As President and CEO of Elucida, Mr. Germano leads strategic efforts to utilize Elucida's ultra-small C-dot cancer targeting particle platform across diagnostic imaging, surgical and therapeutic applications. He served as President of Intrexon Corporation ("Intrexon"), a leader in engineering and industrialization of biology, from June 2016 to March 2017. Prior to joining Intrexon, from 2014 to February 2016 Mr. Germano was Group President of the Global Innovative Pharma Business of Pfizer Inc. ("Pfizer"), where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer, focused on maximizing the return on research and development investment across the Pfizer portfolio from 2013 to 2016. Previously, from 2009 through 2013 Mr. Germano served as President and General Manager of Pfizer's Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets, and as Executive Vice President of the Vaccines Business. Mr. Germano also currently serves on the board of Sage Therapeutics, Inc. From 2008 to 2018 Mr. Germano was a Trustee of the Albany College of Pharmacy & Health Sciences. Mr. Germano received his Bachelor of Science in Pharmacy from Albany College of Pharmacy.
- Michael Amoroso
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Shari Lisa Piré
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Melinda Brown
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Stanley Frankel
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kevin Buehler
-
Kevin Buehler是美国人，Kevin Buehler从2011年4月开始担任爱尔康（Alcon）的部门负责人。他是诺华制药（Novartis）的执行委员会委员。从2009年到2011年，Buehler先生担任爱尔康（Alcon Inc.）的总裁兼首席执行官。他于1984年在爱尔康担任消费者产品部门的地区销售经理而开启其职业生涯，并在被任命为销售与市场部的总监以前，担任过职责递增的职位。他于1996年担任爱尔康的美国管理式照护与猎鹰仿制药品事业部的总监，并于1998年担任副总裁。第二年，他回到美国消费者产品部门担任副总裁兼总经理。Buehler先生于2002年迁至国际部门担任拉丁美洲与加勒比海地区的副总裁兼地区经理。后来他担任拉丁美洲、加拿大、澳大利亚与远东地区的地区副总裁。Buehler先生还担任全球市场部的高级副总裁，并担任首席营销官。加入爱尔康前，他在美国的The Gillette Co.和 Snyder Drug Stores任职。Buehler先生在美国威斯康星州沃基肖市的卡罗尔大学（Carroll University）获得学士学位，主修工商管理与政治学。他于1993年完成哈佛大学（Harvard）的管理发展课程。
Kevin Buehler has served on board of directors since November 2019 and, in March 2020 was appointed Interim Chair of the Board. Mr. Buehler has over 30 years of experience in the healthcare industry, having most recently served from April 2011 to May 2014 as the Division Head of Alcon Laboratories, Inc., a division of Novartis AG, a multinational pharmaceutical company. Prior to that, from April 2009 to April 2011 he served as the Chief Executive Officer and President of Alcon Inc., after having served from 2007 to 2009 as Alcon Inc.'s Senior Vice President, Global Markets and Chief Marketing Officer and, from 2006 to 2007 as its Senior Vice President of the U.S. market and the Chief Marketing Officer. Mr. Buehler began his career with Alcon, Inc. in August 1984. Mr. Buehler holds a B.A. degree from Carroll University in Waukesha, WI, with concentrations in Business Administration and Political Science, and is a graduate of the Harvard Executive Program for Management Development. - Kevin Buehler是美国人，Kevin Buehler从2011年4月开始担任爱尔康（Alcon）的部门负责人。他是诺华制药（Novartis）的执行委员会委员。从2009年到2011年，Buehler先生担任爱尔康（Alcon Inc.）的总裁兼首席执行官。他于1984年在爱尔康担任消费者产品部门的地区销售经理而开启其职业生涯，并在被任命为销售与市场部的总监以前，担任过职责递增的职位。他于1996年担任爱尔康的美国管理式照护与猎鹰仿制药品事业部的总监，并于1998年担任副总裁。第二年，他回到美国消费者产品部门担任副总裁兼总经理。Buehler先生于2002年迁至国际部门担任拉丁美洲与加勒比海地区的副总裁兼地区经理。后来他担任拉丁美洲、加拿大、澳大利亚与远东地区的地区副总裁。Buehler先生还担任全球市场部的高级副总裁，并担任首席营销官。加入爱尔康前，他在美国的The Gillette Co.和 Snyder Drug Stores任职。Buehler先生在美国威斯康星州沃基肖市的卡罗尔大学（Carroll University）获得学士学位，主修工商管理与政治学。他于1993年完成哈佛大学（Harvard）的管理发展课程。
- Kevin Buehler has served on board of directors since November 2019 and, in March 2020 was appointed Interim Chair of the Board. Mr. Buehler has over 30 years of experience in the healthcare industry, having most recently served from April 2011 to May 2014 as the Division Head of Alcon Laboratories, Inc., a division of Novartis AG, a multinational pharmaceutical company. Prior to that, from April 2009 to April 2011 he served as the Chief Executive Officer and President of Alcon Inc., after having served from 2007 to 2009 as Alcon Inc.'s Senior Vice President, Global Markets and Chief Marketing Officer and, from 2006 to 2007 as its Senior Vice President of the U.S. market and the Chief Marketing Officer. Mr. Buehler began his career with Alcon, Inc. in August 1984. Mr. Buehler holds a B.A. degree from Carroll University in Waukesha, WI, with concentrations in Business Administration and Political Science, and is a graduate of the Harvard Executive Program for Management Development.
高管简历
中英对照 | 中文 | 英文- Dario Scimeca
Dario Scimeca自2019年6月起担任我们的总法律顾问。在加入我们之前，Scimeca先生于2013年1月至2019年6月在生物技术公司Genentech（罗氏的美国分支机构）担任过各种职务，包括最近担任助理总法律顾问，在那里他就与多种药物肿瘤学和罕见病产品的开发和商业化相关的法律问题提供咨询。此前，他曾担任Elan Pharmaceuticals公司的公司法律顾问，在那里他曾监管FDA和EMA监管合规事务。他此前曾在三家国家律师事务所从事公司交易法和专利诉讼。Scimeca先生在圣克拉拉大学（Santa Clara University）获得学士学位，在加州大学伯克利分校法学院（University of California，Berkeley）获得法学博士学位，并在路易斯安那州新奥尔良的美国第五巡回上诉法院（United States Fifth Circuit Court of Appeals）为詹姆斯·丹尼斯（James L.Dennis）法官担任书记员。
Dario Scimeca has served as General Counsel since June 2019. Prior to joining us, Mr. Scimeca served in various roles for Genentech, a biotechnology company, U.S. affiliate of Roche, from January 2013 to June 2019 including most recently as Assistant General Counsel, where he counseled on legal issues associated with the development and commercialization of multiple drug oncology and rare disease products. Prior to that, he was corporate counsel at Elan Pharmaceuticals where he, among other things, oversaw FDA and EMA regulatory compliance matters. He has previously worked in both corporate transactional law and patent litigation at three national law firms. Mr. Scimeca received a B.S. from Santa Clara University, his J.D. from the University of California, Berkeley, School of Law, and clerked for Judge James L. Dennis on the United States Fifth Circuit Court of Appeals in New Orleans, Louisiana.- Dario Scimeca自2019年6月起担任我们的总法律顾问。在加入我们之前，Scimeca先生于2013年1月至2019年6月在生物技术公司Genentech（罗氏的美国分支机构）担任过各种职务，包括最近担任助理总法律顾问，在那里他就与多种药物肿瘤学和罕见病产品的开发和商业化相关的法律问题提供咨询。此前，他曾担任Elan Pharmaceuticals公司的公司法律顾问，在那里他曾监管FDA和EMA监管合规事务。他此前曾在三家国家律师事务所从事公司交易法和专利诉讼。Scimeca先生在圣克拉拉大学（Santa Clara University）获得学士学位，在加州大学伯克利分校法学院（University of California，Berkeley）获得法学博士学位，并在路易斯安那州新奥尔良的美国第五巡回上诉法院（United States Fifth Circuit Court of Appeals）为詹姆斯·丹尼斯（James L.Dennis）法官担任书记员。
- Dario Scimeca has served as General Counsel since June 2019. Prior to joining us, Mr. Scimeca served in various roles for Genentech, a biotechnology company, U.S. affiliate of Roche, from January 2013 to June 2019 including most recently as Assistant General Counsel, where he counseled on legal issues associated with the development and commercialization of multiple drug oncology and rare disease products. Prior to that, he was corporate counsel at Elan Pharmaceuticals where he, among other things, oversaw FDA and EMA regulatory compliance matters. He has previously worked in both corporate transactional law and patent litigation at three national law firms. Mr. Scimeca received a B.S. from Santa Clara University, his J.D. from the University of California, Berkeley, School of Law, and clerked for Judge James L. Dennis on the United States Fifth Circuit Court of Appeals in New Orleans, Louisiana.
- Michael Amoroso
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- John Alexander Kelly
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeff Smith
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介